Head and Neck Cancer (Oral, Larynx, Pharynx) Surgery Cost Calculator
This calculator estimates the out-of-pocket cost of head and neck cancer treatment in Korea and keeps the same pure calculation model as the Korean page. Head and neck cancer is a squamous-cell cancer of the upper aerodigestive tract: oral cavity cancer (lip, tongue, gum, floor of mouth; C00–C06), laryngeal cancer (C32), and pharyngeal cancer (tonsil and oropharynx, nasopharynx, hypopharynx; C09–C14). The cost depends on the site and the treatment chosen — wide excision with neck dissection, total laryngectomy, transoral robotic surgery (TORS), or larynx-preserving concurrent chemoradiation (CCRT) — and can range from a few million to tens of millions of won. The single most important rule is the cancer special case: because every head and neck cancer is a malignant C-code, a registered patient pays 5% instead of 20% for five years, regardless of the site. All figures use 2026 Korean rules.
Wide excision vs total laryngectomy vs TORS vs larynx-preserving CCRT
Wide excision with neck dissection is the standard head and neck cancer operation: the primary tumor is removed with a safe margin and the neck lymph nodes are cleared. When the resulting defect is large, a microvascular free flap (radial forearm, anterolateral thigh, or fibula) reconstructs it to preserve swallowing and speech, which lengthens the ICU and ward stay for flap monitoring. Total laryngectomy removes the whole larynx for advanced laryngeal cancer; it can cure the disease but leaves a permanent neck stoma and the loss of natural voice, so disability registration and voice rehabilitation (electrolarynx, esophageal speech, or a tracheoesophageal puncture) must be planned.
Transoral robotic surgery (TORS) reaches an oropharyngeal or laryngeal tumor through the mouth with the da Vinci robot, so there is no external incision and recovery is fast — useful for early-stage, HPV-related oropharyngeal cancer. The robot fee, however, is non-covered (out of pocket) in Korea, so the special-case 5% applies only to the covered resection fee, not the robot cost. Concurrent chemoradiation (CCRT) gives radiation (about 33–35 fractions) with cisplatin to preserve the larynx without surgery; it avoids laryngectomy but requires management of mucositis, dysphagia, and dry mouth, and a salvage laryngectomy may be needed if the cancer recurs.
- Wide excision + neck dissection: covered procedure ~KRW 8,000,000, ward 12–16 days; free flap adds a covered reconstruction fee and extra ICU/ward days.
- Total laryngectomy: covered ~KRW 9,500,000, 16–21 day stay, permanent stoma and voice loss.
- TORS: covered resection ~KRW 4,500,000 plus a NON-COVERED robot fee ~KRW 9,000,000 (out of pocket).
- Larynx-preserving CCRT: covered ~KRW 7,000,000, mostly outpatient over ~7 weeks.
The cancer special case covers every head and neck site at 5%
The biggest cost driver is the cancer (severe-disease) special case, registration code V193. Its eligible diagnosis codes are the malignant neoplasm range C00–C97, which includes all head and neck cancers — oral cavity (C00–C06), pharynx (C09–C14), and larynx (C32). Unlike a brain tumor, where benign versus malignant coding matters, every head and neck cancer is malignant, so registration always drops the covered self-pay from 20% to 5%.
The special case lasts five years from the confirmation date and can be re-registered if the cancer recurs or persists. If you register within 30 days of diagnosis, it applies retroactively to the confirmation date; later registration applies from the application date. Within the five years, the 5% rate also covers outpatient radiation, chemotherapy, and follow-up imaging, not just the surgery.
- Oral cavity (C00–C06): lip, tongue, gum, floor of mouth — 5% special-case self-pay for 5 years.
- Larynx (C32): laryngectomy or larynx-preserving CCRT both at 5%.
- Pharynx (C09–C14): tonsil/oropharynx, nasopharynx, hypopharynx — 5% for 5 years.
- The TORS robot fee is non-covered, so it is outside the special case and the out-of-pocket ceiling.
Free flap reconstruction, adjuvant chemoradiation, and voice loss
A large oral or pharyngeal defect after wide excision is reconstructed with a microvascular free flap, a covered add-on in the calculator; because it is covered, the special-case 5% applies, but flap monitoring lengthens the ICU and ward stay. High-risk patients (positive margins, multiple positive nodes) receive postoperative adjuvant chemoradiation with cisplatin, also a covered add-on. These covered items keep the out-of-pocket ceiling in play for long admissions.
After total laryngectomy the airway and esophagus are separated, leaving a permanent stoma and the loss of natural voice. Patients should plan for laryngeal (speech) disability registration and voice rehabilitation — an electrolarynx, esophageal speech, or a tracheoesophageal puncture (TEP) — some of which is non-covered. HPV-related oropharyngeal cancer often has a good prognosis and is increasingly treated with TORS or radiation, while nasopharyngeal cancer is usually treated with chemoradiation rather than surgery.
Out-of-pocket ceiling, private indemnity, and tax credit
The annual out-of-pocket ceiling refunds covered self-pay (including the 5% special-case amount) above the income-tier cap, which for 2026 is provisionally about KRW 900,000 to KRW 8,430,000 by income decile (finalized each August). Non-covered items — the TORS robot fee, selective benefits, and upper-grade room surcharges — are excluded from the ceiling, so they belong to the private indemnity (silson) domain, where covered self-pay is reimbursed after the generation-specific deductible, non-covered costs are reimbursed at the non-covered rate, and the room surcharge is usually paid at only 50%.
For the medical expense tax credit, a registered severe-disease (cancer) patient has no KRW 7,000,000 cap under Income Tax Act Article 59-4 — the full out-of-pocket amount above 3% of salary is credited at 15%, while an unregistered patient keeps the KRW 7,000,000 cap. Private insurance reimbursement and the ceiling refund are excluded from the credit base, so the estimate is computed on the true net out-of-pocket amount, including non-covered rehabilitation.
How to read the result
Enter the cancer site (oral, larynx, or pharynx), the treatment (wide excision, laryngectomy, TORS, or CCRT), special-case registration, and — for surgery — whether a free flap reconstruction or adjuvant chemoradiation is added, plus ICU and ward days, hospital level, indemnity generation, and income decile. The result shows the 20% versus 5% special-case comparison, a four-way treatment comparison (with the TORS robot non-covered cost included), the ceiling refund, the private indemnity estimate, the tax credit, and the final net cost.
This is a cost-planning estimate based on 2026 Korean rules, not medical advice. Public single-price tables for head and neck cancer surgery do not exist, so figures are defensible market-estimate ranges that vary with the site, the extent of resection, whether a free flap is used, length of stay, complications, and hospital. Confirm details with the treating head and neck surgery team, the insurer, and the hospital quote — especially the non-covered TORS robot fee.
This calculator is based on Korean rules (2026 National Health Insurance cancer special-case program covering all head and neck cancer codes C00–C14 and C32 at 5% for five years, free flap reconstruction as a covered add-on, the TORS robot fee as a non-covered cost, the out-of-pocket ceiling, and Income Tax Act Article 59-4 medical expense tax credit), plus market cost estimates for wide excision with neck dissection, total laryngectomy, transoral robotic surgery, and larynx-preserving chemoradiation. Figures are planning estimates, not medical advice, an insurer decision, or a hospital quote.